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An acute increase in the circulating concentration of glucocorticoid
hormones is essential for the survival of severe somatic stresses.
Circulating concentrations of GDF15, a hormone that acts in the brain
to reduce food intake, are frequently elevated in stressful states.
We now report that GDF15 potently activates the hypothalamic–
pituitary–adrenal (HPA) axis in mice and rats. A blocking antibody
to the GDNF-family receptor α-like receptor completely prevented
the corticosterone response to GDF15 administration. In wild-type
mice exposed to a range of stressful stimuli, circulating levels of both
corticosterone and GDF15 rose acutely. In the case of Escherichia coli
or lipopolysaccharide injections, the vigorous proinflammatory cyto-
kine response elicited was sufficient to produce a near-maximal HPA
response, regardless of the presence or absence of GDF15. In contrast,
the activation of the HPA axis seen in wild-type mice in response to
the administration of genotoxic or endoplasmic reticulum toxins,
which do not provoke a marked rise in cytokines, was absent in
Gdf15−/− mice. In conclusion, consistent with its proposed role as a
sentinel hormone, endogenous GDF15 is required for the activation of
the protective HPA response to toxins that do not induce a substantial
cytokine response. In the context of efforts to develop GDF15 as an
antiobesity therapeutic, these findings identify a biomarker of target
engagement and a previously unrecognized pharmacodynamic effect,
which will require monitoring in human studies.
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The activation of the hypothalamic–pituitary–adrenal (HPA)axis, which results in an increase in circulating glucocorti-
coids, is a stereotypical response to a wide range of stressful stimuli.
Through their antiinflammatory, metabolic, and vasomotor effects,
glucocorticoid hormones assist the organism in withstanding life-
threatening challenges (1).
While the HPA axis responds acutely to a range of external
threats perceived by dedicated sensors, it is also responsive to the
status of the internal milieu. Thus, in the context of infection or
severe tissue damage, proinflammatory cytokines, such as TNFα/β,
IL-1, and IL-6, activate the axis (reviewed in ref. 2). During starva-
tion, a fall in circulation leptin concentrations is sensed by the hy-
pothalamus and conveyed to the corticotropin-releasing hormone
(CRH) neurons, which initiate the HPA response (3). More recently
it has been recognized that fibroblast growth factor 21 (FGF21), a
largely hepatically derived hormone, the levels of which are increased
by prolonged fasting, can also activate the HPA axis (4).
Threats to the organism can also arise from noninfectious agents,
such as ionizing radiation, temperature, hypoxia, or the accidental
ingestion of, or envenomation by, toxic chemicals. Exposure to the
latter is likely to have played an important evolutionary role as a
surprisingly large percentage of the genome of metazoan organisms,
the so-called “chemical defensome,” is devoted to genes concerned
with the recognition, inactivation, and disposition of xenobiotic
substances (5). Earlier literature contains several reports of in-
creases in circulating glucocorticoid levels in rodents occurring in
response to a range of toxins, including honey bee and snake venom
(6, 7), cyanide (8), and purified diphtheria toxin (8). More recently,
genotoxins such as cisplatin have been shown to activate the HPA
axis in dogs and rats (9, 10).
Unbiased transcriptomic screens of cellular responses to chem-
ical toxins have frequently identified the transforming growth
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factor beta (TGF-β) superfamily member, growth differentiation
factor 15 (Gdf15), as one of the most highly up-regulated genes
(11, 12). GDF15 is ubiquitously produced in the body, with circu-
lating concentrations rising rapidly upon exposure to a wide variety
of stressors (12, 13).
GDF15 signals via a heterodimeric receptor, GDNF-family re-
ceptor α-like (GFRAL)-RET, localized specifically in the brain-
stem (14–17). To date, reports of the central actions of GDF15 in
mammals have largely focused on regulation of food intake an-
orexia, weight loss (18–20), emesis (21), pica (22), delayed gastric
emptying (23, 24), and conditioned aversion (25). Recent data
indicate that GDF15 administration also reduces physical activity
in mice (26). This range of actions would be consistent with GDF15
playing a role in signaling the presence of chemical threats to the
organism which might be mitigated by reduced rate of exposure to,
or expulsion of, ingested toxins and the promotion of their avoid-
ance in future.
We undertook a set of experiments to examine whether GDF15
might be involved in the HPA response to stress; possibly syner-
gizing with cytokines in the case of infections and/or playing a more
prominent role in the response to chemical stressors (27). As ex-
amples of the latter, we chose the genotoxin, cisplatin, known to
elevate circulating levels of both corticosterone (9, 10) and GDF15
(21, 22) and the well-established inducer of endoplas mic reticulum
(ER) stress, tunicamycin. ER stress is mechanistically distinct from
genotoxicity and its effects to increase GDF15 expression and se-
cretion are well established (20, 28).
We now report that GDF15, acting through its receptor,
GFRAL, is a powerful activator of the HPA axis. While its en-
dogenous concentration rises in response to infectious stimuli,
GDF15 is not necessary for the activation of the HPA axis. In
contrast, the robust HPA activation that results from exposure to
chemical stressors, which do not cause a substantial rise in proin-
flammatory cytokines, is highly dependent on GDF15.
Results
Exogenous GDF15 Activates the HPA Axis in a GFRAL-Dependent
Manner. We sought to determine whether GDF15 activated the
HPA axis in mice. We used recombinant human GDF15 at a
dose (0.1 mg/kg) that has previously been shown to significantly
reduce food intake (20). Mice housed at standard temperature
were injected with GDF15, or vehicle, with subsequent blood
samples taken at 1 and 4 h postinjection. Corticosterone con-
centrations increased ∼3.5 fold at 1 h and were still significantly
elevated at 4 h post-GDF15 treatment (Fig. 1A). The peak cir-
culating concentrations of human GDF15 achieved in the mice
(Fig. 1B) were comparable to those reported in states such as
severe sepsis (29). This effect was confirmed in both sexes (SI
Appendix, Fig. S1 A and B) and discernible as early as 30 min
postinjection (SI Appendix, Fig. S1C). Similar results were
obtained when studies were performed at thermoneutrality to avoid
any possible effect of cold stress from standard housing temperature
(Fig. 1 C and D). We also studied a lower dose of GDF15
(0.03 mg/kg) under the same conditions. This produced circulating
concentrations of human GDF15 (Fig. 1D) similar to that reported
in patients with cancer and heart failure (30, 31). This dose also
resulted in a significant increase in circulating corticosterone, which
was almost as marked as that seen with the higher dose (Fig. 1C).
The corticosterone response to GDF15 was not attributable to any
acute reduction in circulating leptin concentration, which was not
significantly changed at 1 h (SI Appendix, Fig. S1D).
To determine whether the corticosterone response to GDF15
was specifically mediated through its hindbrain receptor, we un-
dertook experiments using a neutralizing anti-GFRAL antibody,
having validated its efficacy on classical GDF15 responses in mice.
At a dose of 20 mg/kg, the antibody blocked GDF15-induced
food intake reduction and body weight loss (SI Appendix, Fig.
S1 E and F andMethods). Furthermore, the anti-GFRAL antibody
completely prevented GDF15-induced corticosterone concentra-
tions while a control isotype antibody had no effect (Fig. 1E). The
concentrations of human circulating GDF15 achieved in the study
did not differ between the anti-GFRAL group and control isotype
(Fig. 1F).
As the increase of circulating glucocorticoids is centrally driven
by a discrete population of CRH neurons in the paraventricular
nucleus (PVN) of the hypothalamus and GDF15 administration
has been shown to activate this region (32), we used dual in situ
hybridization (RNAScope) to examine the expression of c-Fos and
Crh in the mouse hypothalamus under basal conditions and in
response to the peripheral administration of GDF15. The mice
were killed at 1 h postinjection and hypothalamic sections were
prepared and stained. GDF15 significantly increased the propor-
tion of Crh neurons expressing c-Fos, thus confirming activation of
Crh-expressing neurons (Fig. 1 G and H).
The effect of chronic exposure to GDF15 was also investigated
in cannulated rats, which allowed serial sampling and measurement
of adrenocorticotropic hormone (ACTH) as well as corticosterone,
with minimal handling stress. GDF15 (or vehicle) was administered
as an acute bolus over 1 h followed by 5 d of sustained infusion (SI
Appendix, Fig. S2A). After 1 h of GDF15 infusion, the concen-
trations of human GDF15 peaked and were sustained at 100 to
150 ng/mL throughout the study (Fig. 2A). The efficacy of human
recombinant GDF15 was validated by the suppression of food in-
take by up to 70% accompanied by a 16% reduction of body weight
(SI Appendix, Fig. S2 B and C). Compared to vehicle-treated ani-
mals, corticosterone levels rose significantly at 4 h. With chronic
infusion, corticosterone levels declined from their initial peak but
tended to remain higher in the GDF15-infused animals throughout
all of the infusion period (Fig. 2B). Supporting a central rather
than peripheral effect of GDF15, we found that ACTH levels were
significantly higher than the vehicle-infused animals throughout the
experiment (Fig. 2C). This is noteworthy as corticosterone exerts
strong negative feedback on CRH release. The maintenance of
elevated ACTH levels under circumstances where corticosterone
levels are the same or slightly higher than vehicle-infused animals
indicates a sustained action of GDF15 to stimulate the axis.
We then proceeded to perform a series of experiments designed
to examine the role of endogenous GDF15 as a stimulus to the
HPA axis in response to a variety of stressors.
Infection-Induced Activation of the HPA Axis Does Not Require GDF15.
It is well established that proinflammatory cytokines can activate
the HPA axis in the context of systemic infections. Circulating
GDF15 levels are also elevated in response to infectious stimuli
in humans and mice (33, 34). We therefore wished to test
whether a rise in circulating GDF15 in this context might con-
tribute to the activation of the HPA axis effects. We did this by
examining the HPA response in wild-type and Gdf15-deficient
mice (Gdf15−/−) to two different infection-related stimuli: 1) li-
popolysaccharide (LPS)-induced endotoxemia and 2) systemic
infection with Escherichia coli.
The administration of LPS at 0.5 mg/kg produced a robust in-
crease in circulating GDF15 (Fig. 3A). LPS also induced a rise in
corticosterone (Fig. 3B), which was similar in wild-type or Gdf15−/−
mice at the time point analyzed (2 h). As expected, GDF15 (SI
Appendix, Fig. S3A), corticosterone (SI Appendix, Fig. S3B), and
cytokine levels were markedly increased by LPS injection at all time
points analyzed (SI Appendix, Table S1) to an extent that was in-
dependent of GDF15 status. In the experiments undertaken with a
lower dose of LPS (0.05 mg/kg) corticosterone responses were again
very similar in wild-type and Gdf15−/− mice (Fig. 3C).
In independent experiments Gdf15−/− mice or their wild-type
controls were injected with either E. coli or vehicle as previously
described (35). The rise in corticosterone occurred at 4 h but was
not different between the two genotypes (Fig. 3D).
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Fig. 1. Acute administration of human recombinant GDF15 activates the HPA axis in mice. (A and B) Mouse study 1 (MS1) at standard housing condition: acute effect of
human recombinant GDF15 administration on (A) endogenous corticosterone and (B) human GDF15 plasma concentration at 1 h and 4 h post-GDF15 treatment. (C andD)
MS2 at thermoneutral housing condition: acute effect of two doses of human recombinant GDF15 on (C) plasma corticosterone and (D) humanGDF15 concentrations after
1-h treatment (0.03 and 0.1 mg/kg). (E and F) MS3: (E) Corticosterone serum level in anti-GFRAL- and IgG control-treated mice with or without human recombinant GDF15
administration. (F) Human GDF15 serum concentration in GFRAL blocking antibody (anti-GRFAL) and IgG groups treated with human recombinant GDF15. (G and H) MS4:
(G) In situ hybridization analysis of CrhmRNA (red), c-FosmRNA (blue-green), and hematoxylin counterstain for nuclei at the level of the PVN. Left, representative images of
coronal sections of vehicle (Upper Left) and GDF15-treated mice (Lower Left). (Scale bar, 50 μm.) 3V, third ventricle. Middle, higher magnification of the PVN showing
coexpression of Crh and c-Fos dots in vehicle (Upper Middle) and GDF15 treated (Lower Middle). (Scale bar, 100 μm.) Right, automated quantification of Crh- and c-Fos-
positive cells in vehicle (Upper Right) and GDF15-treated mice (Lower Right) (Scale bar, 100 μm.) Black arrows indicate double-labeled cells. Cell nucleus color in the overlay
(Right) represents the cell classification (muted red for Crh-positive cells, bright red for dual-positive cells), while nucleus color intensity correlates with spot counts per cell.
Bright blue spots represent c-Fos spot assigned to a Crh-positive cell. (H) Percentage of Crh-positive cells thatwere also c-Fos positive. Data are expressed asmean± SEM, n=
6 to 8 per group. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, for MS1, -2, and -3, data were analyzed by ANOVA and for MS4, by unpaired Student’s t test.
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Consistent with a largely GDF15-independent effect of infection
on the HPA axis, in human participants injected with low-dose
endotoxin the acute rise in cortisol as well as inflammatory fac-
tors preceded the rise in GDF15 (Fig. 3 E and F and SI Appendix,
Fig. S3 C–E).
Thus, although GDF15 levels increased markedly in response to
infection-related stimuli, this was not necessary for the activation
of the HPA axis. It appears likely that proinflammatory cytokines
such as IL-6, IL-1β, and TNF-α, all of which were significantly
increased post-LPS challenge, play the dominant role under these
circumstances. Indeed, the levels of corticosterone reached with
these powerful infection-related stimuli may be close to maximal,
thereby obscuring any effects of GDF15.
The Glucocorticoid Response to Chemical Toxins Is GDF15 Dependent.
Other than infections, there are a range of potentially life-
threatening stressors to which an organism may be exposed (36)
and many of these have been reported to induce the expression of
GDF15 (11). We chose to examine the role of GDF15 in the ac-
tivation of the HPA in response to exposure to chemical toxins. We
selected cisplatin as a genotoxin and tunicamycin as an inducer of
ER stress.
Previous studies have reported that cisplatin significantly in-
creases circulating GDF15 levels in humans and in preclinical
models (17, 21, 22) We first studied the effects of cisplatin on the
HPA axis in Gdf15−/− mice and wild-type littermates. Independent
studies were undertaken at standard and thermoneutral housing
temperatures. Under both conditions, as expected, cisplatin caused
a robust rise in circulating GDF15 andGdf15mRNA in the liver in
wild-type but not inGdf15−/− mice (Fig. 4 A, C,D, and F). Notably,
corticosterone levels increased approximately threefold at 6 h in
the wild-type mice and not in the Gdf15−/− mice (Fig. 4 B and E).
In contrast to infectious models, cisplatin does not increase circu-
lating levels of proinflammatory markers during the time course of
these experiments (21).
GDF15 is known to be potently induced by ER stress (20, 28,
37). We chose to use tunicamycin, a bacterially derived inhibitor
of N-linked protein glycosylation, as an ER stressor for in vivo
studies in mice at standard and thermoneutral conditions.
Six hours after tunicamycin treatment, we observed an increase
in circulating GDF15 (Fig. 5 A and H) and in the hepatic expres-
sion of Gdf15 mRNA in the wild-type mice (Fig. 5 D and K). As
expected, we also observed an increase in the hepatic levels of
mRNA encoding the classical ER stress markers Atf4 and Chop in
both Gdf15−/− and wild-type mice (Fig. 5 E, F, L, and M). In
contrast to cisplatin, tunicamycin treatment did result in a rise in
the circulating levels of some proinflammatory cytokines, but this
was limited to a minority of those assayed and modest in extent,
being far less than the rise observed in response to LPS. At the 6-h
time point, when the HPA axis was assessed, only IL-12 was ele-
vated in both wild-type andGdf15−/− mice (SI Appendix, Table S2),
with no substantial induction of TNF-a, IL-6, or IL-1β, proin-
flammatory cytokines previously shown to activate the HPA axis
(38, 39).
We proceeded to study the effects of tunicamycin on the HPA
axis in Gdf15−/− and wild-type mice. Six hours after tunicamycin,
corticosterone levels were elevated threefold in the wild-type mice,
and the response was markedly attenuated in the Gdf15−/−animals
(Fig. 5 B and I).
Hepatic ER stress is also known to increase the expression and
secretion of FGF21, an endocrine member of the fibroblast
Fig. 2. Chronic infusion of human GDF15 activates the HPA axis in rats. Rat study 1 (RS1): (A) Plasma concentration time course of human GDF15 in rats with
continuous intravenous infusion of vehicle or human GDF15. Gray shade indicates the period with bolus infusion of 0.24 mg/kg/h followed by a period with
maintenance infusion of 0.04 mg/kg/h. (B) Plasma concentration time course of endogenous corticosterone in rats in response to continuous intravenous
infusion of vehicle buffer or human GDF15. Plasma corticosterone levels are expressed as the area under the curve (AUC) calculated from time point zero to
the termination of the study. (C) Plasma concentration time course of endogenous ACTH in rats in response to continuous intravenous infusion of vehicle or
human GDF15. Plasma corticosterone levels expressed as the AUC calculated from time point zero to the termination of the study. Data are expressed as
mean ± SEM, n = 5 to 6. *P < 0.05 **P < 0.01, ****P < 0.0001 by repeated measurement model with baseline assessment as a covariate.
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growth factor (FGF) family, which is known to act in the brain
where, among other effects, it can also activate the HPA axis.
Since tunicamycin-induced corticosterone is partially GDF15
dependent, we measured circulating FGF21 level in mice after
tunicamycin injection. Tunicamycin increased circulating FGF21
(Fig. 5 C and J) and also Fgf21mRNA levels in the liver (Fig. 5G
and N).
To examine the relative importance of GDF15 and FGF21 in
mediating the effect of tunicamycin-induced ER stress on the
HPA axis, we studied mice lacking FGF21 (Fgf21−/−) as well as
mice doubly null for Fgf21 and Gdf15 (Gdf15−/−:Fgf21−/−).
Fgf21−/− mice responded to tunicamycin with a corticosterone
response that was indistinguishable from the wild type (Fig. 6). In
contrast, the double-deficient mice showed no discernible cor-
ticosterone response to tunicamycin (Fig. 6). We conclude that
while FGF21 may make a small contribution to the effects of
ER stress on the HPA axis, GDF15 is clearly the dominant
signal.
Fig. 3. GDF15 is not necessary in mediating the LPS-induced rise in glucocorticoids in mice and humans. MS5: (A) Mouse GDF15 and (B) corticosterone serum
concentrations at baseline (time = 0) and 2 h after LPS (0.5 mg/kg) or vehicle control injection in wild-type and Gdf15−/− mice. (C) Corticosterone serum
concentration 2 h after LPS (0.05 mg/kg) or vehicle control injection in wild-type and Gdf15−/− mice. (D) MS6: Corticosterone serum concentration 4 h after
E. coli infection in wild-type and Gdf15−/− mice. (E and F) Human study 1 (HS1): Time course of (E) GDF15 and (F) cortisol serum levels at baseline (time = 0)
and after 2 ng/kg bolus intravenous infusion of LPS in healthy human subjects. For MS5 and MS6 data are expressed as mean ± SEM, n = 4 to 6 per group. *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by ANOVA. For HS1 data are expressed as mean ± SEM, n = 11. *P < 0.05, ***P < 0.001 by one-way repeated
measures with post hoc Dunnett’s test to compare each time point with baseline.
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Since its identification in 1997 as a novel endocrine member of
the TGF-β superfamily expressed in activated macrophages (40),
circulating levels of GDF15 have been reported to be elevated in
a broad spectrum of conditions, including many disease states (reviewed
in refs. 12 and 13). GDF15 expression can be induced in many, perhaps
all, tissues in response to a variety of different stressful stimuli (reviewed
in refs. 12 and 13). The identification of a brainstem-restricted re-
ceptor and of a wide range of centrally controlled behavioral and
gastrointestinal responses have led to the suggestion that GDF15
may be a “sentinel” hormone. The role of such a signal would include
limiting systemic exposure to recently ingested toxins (through its
effect on vomiting and pica) and, through its induction of condi-
tioned aversion, promoting the avoidance of future exposures to
agents, which have previously led to cellular stress in the host (12).
We now describe another important action of GDF15, namely
the activation of the HPA axis. This occurs acutely at levels of
circulating GDF15, similar to those found naturally in response to
various stressors and illnesses, and requires GFRAL (41, 42).
Hindbrain neurons expressing GFRAL project to the parabrachial
nucleus (32, 43) and from that nucleus, there are well-established
projections to the PVN (44) where CRH-expressing neurons were
activated by GDF15. Endogenous GDF15 was not required for
the HPA response to infection-related stimuli but was essential for
the response to the administration of toxins of two different
classes. It is worthy of note that, consistent with the acutely life-
threatening nature of systemic infections, peak corticosterone levels
occurring as a result of infection-related stimuli are substantially
higher than those found after the administration of the toxins or
after the administration of high doses of GDF15. It seems reason-
able to speculate that the cytokine “storm,” which occurs in response
to LPS or E. coli injection, results in a maximal or near-maximal
activation of the HPA axis, rendering any additional input to the axis
from signals emanating from GDF15-activated neurons in the
hindbrain redundant under those circumstances.
GDF15 levels rise in response to a very broad range of inju-
rious agents, including ionizing radiation (45), hypoxia (46), in-
tense physical activity (47), and a wide range of chemical toxins
all of which can activate a stress response and many of which also
elevate GDF15 (11, 12) but not all of which cause an acute cy-
tokine response (21). We examined two agents known to increase
circulating GDF15, one of which is genotoxic (cisplatin) (21, 22)
and the other, tunicamycin, which produces marked ER stress by
perturbing protein folding (20, 28). Both agents resulted in a
marked increase in both GDF15 and corticosterone. Cisplatin has
previously been reported to activate the HPA axis in rats and dogs
(9, 10). There is one report in humans (48), which describes the
opposite effect but blood sampling in this study was limited to the
first 6 h after drug administration and to a small number of patients.
To our knowledge, there are no previous reports of the effects of
systemically administered ER stressors on the HPA axis.
In a previous study we found no significant rise of proinflammatory
cytokines in response to cisplatin (21). In our study the rise in
corticosterone in response to cisplatin was absent in the mice
lacking GDF15, whether housed at standard or thermoneutral
temperatures. In the case of the ER stress response to tunicamycin
there were small increases in some proinflammatory cytokines, but
these were orders of magnitude lower than concentrations observed
Fig. 4. GDF15 is necessary to mediate corticosterone rising upon cisplatin administration. MS7 at standard housing temperature: (A) Mouse GDF15 and (B)
corticosterone plasma concentration and (C) Gdf15 mRNA expression in the liver after 6-h cisplatin administration (10 mg/kg) in wild-type and Gdf15−/− mice.
(D–F) MS8 at thermoneutral housing condition: (D) Mouse GDF15 and (E) corticosterone plasma concentration and (F) Gdf15 mRNA expression in the liver
after 6-h cisplatin injection (10 mg/kg) in wild-type and Gdf15−/− mice. Data are expressed as mean ± SEM, For MS7, n = 8 to 9 per group, MS8, n = 13 to 16 per
group, ****P < 0.0001 by ANOVA.
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in response to infection-related stimuli, and in particular there was
no substantial induction of TNF-a, IL-1β, and IL-6, the cytokines
best described to induce the HPA axis.
Although FGF21 is also induced by ER stress (49), our ex-
periments clearly demonstrated the dominance of GDF15 in
mediating the HPA response to this type of cellular stress.
Fig. 5. GDF15 is partially needed to mediate corticosterone rising upon tunicamycin-induced ER stress. (A–G) MS9 at standard housing temperature: (A)
Mouse GDF15, (B) corticosterone, and (C) FGF21 serum levels after 6-h tunicamycin injection in wild-type and Gdf15−/− mice. mRNA expression of (D) Gdf15,
(E) Atf4, (F) Chop, and (G) Fgf21 in the liver after 6-h tunicamycin injection in wild-type and Gdf15−/− mice. (H–N) MS10 at thermoneutral housing condition:
(H) Mouse GDF15, (I) corticosterone, and (J) FGF21 plasma levels after 6-h tunicamycin injection in wild-type and Gdf15−/− mice. (K) Gdf15, (L) Atf4, (M) Chop,
and (N) Fgf21 mRNA expression in the liver after 6-h tunicamycin injection. Data are expressed as mean ± SEM, n = 5 to 9 per group. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 by ANOVA.
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We have previously argued that GDF15 actions on the brain do
not necessarily represent part of a homeostatic system controlling
appetite and body weight but are more likely to represent an
“allostatic” system involved in the response of the organism to
major threats (20, 50). Activation of the HPA axis is a core feature
of the response to a wide range of threats. The existence, in
metazoan genomes, of a wide variety of highly conserved genes—
the principal purpose of which appears to be to detect, inactivate,
and dispose of xenobiotic substances—suggest that exposure to
chemical stressors has been an omnipresent evolutionary pressure
(51). It is therefore unsurprising to find that a system appears to
have evolved to activate a key endocrine arm of the stress response
after exposure to chemically activated cellular stress.
In addition to identifying a physiological/allostatic role for
GDF15, the finding that it potently activates the HPA axis opens
up a range of relevant questions in translational biomedicine.
Could the effect in the HPA axis contribute to the development
of diseases where levels of GDF15 are pathologically elevated?
There are several human diseases where GDF15 concentrations
are chronically elevated (52, 53). Many of these are associated
with cachexia (54, 55), characterized by loss of fat and muscle
mass (56). The effects of GDF15 on appetite and body weight
have been well established, but glucocorticoids are powerfully
antianabolic in skeletal muscle, raising the question of whether
the loss of lean mass, particularly in skeletal muscle, could be
attributed to the chronic activating effects of GDF15 on the
HPA axis. It is worthy of note that we have recently reported an
effect of glucocorticoids to suppress GDF15 levels, indicating
that the interaction is bidirectional (57).
Our findings may also have implications for the development of
GDF15 agonists as therapeutics for obesity and related metabolic
disorders. Because of its action as an appetite suppressant, GDF15
is being explored as a potential therapy for obesity. Safety issues
are central to the development of antiobesity therapeutics. As
GDF15 analogs and agonists of its receptor are developed further
as antiobesity agents, it may be relevant to determine the extent
and durability of its actions on the HPA axis.
GDF15 has been reported to have antiinflammatory properties
under various circumstances (35, 58–60). It has therefore been
suggested that, in addition to reducing food intake and body
weight, GDF15 might have additional potential therapeutic util-
ity in ameliorating the inflammatory component of many car-
diometabolic diseases (58, 61). The means by which GDF15 could
exert its putative antiinflammatory actions have been obscure.
Given the powerful antiinflammatory properties of corticoste-
roids, the additional action of GDF15, which we describe herein, is
an obvious route through which such effects could be mediated.
That said, other research has suggested that GDF15 can, under
certain circumstances, be proinflammatory (62, 63) and Luan et al.
recently reported that GDF15 promoted survival in the face of
serious infection through effects on host tolerance rather than host
defense without affecting the magnitude of the inflammatory re-
sponse (34). This is an area that clearly requires further research.
Conversely, GDF15 antagonists are being developed to treat
cachectic states, particularly those associated with cancer (64). In
addition to improving appetite and food intake, GDF15 block-
ade might improve the anabolic state and increase muscle mass
through reversing pathological hyperactivation of the HPA axis.
GDF15 blockade is also being explored for its utility in reducing
the side effects of cytotoxic chemotherapy particularly with
platinum-based reagents (21). Further studies of the impact of
GDF15 neutralization on the HPA in these circumstances are
warranted.
In conclusion, the chemical defensome appears to have an en-
docrine circuit, in which GDF15 constitutes the afferent limb,
transmitting signals of toxin-induced cellular stress to the brain, with
glucocorticoids being the efferent hormonal output. This aspect of
GDF15 action has important consequences for the evaluation of
agonists and antagonists of the GDF15 signaling pathway as
potential therapeutics for a range of human diseases.
Methods
Mice. Briefly, adult wild-type and Gdf15−/−mice were housed individually under
a standard 12 h light:dark cycle (6:00 h:18:00 h) at standard housing tempera-
tures (22 ± 1 °C) or thermoneutral conditions (27 ± 1 °C) with a humidity-
controlled environment. Mice were given ad libitum access to food and wa-
ter. Studies were carried out at three sites: Pfizer Inc, Cambridge, MA, the
University of Cambridge, Cambridge, UK, and the Instituto Gulbenkian de
Ciência (IGC), Portugal. Further details can be found in SI Appendix. At the
University of Cambridge, the research was regulated under the Animals (Sci-
entific Procedures) Act 1986 Amendment Regulations 2012 following ethical
review by the University of Cambridge Animal Welfare and Ethical Review
Body. At IGC, all animal studies were performed in accordance with Portuguese
regulations and approved by the Instituto Gulbenkian de Ciência Ethics Com-
mittee and Direção Geral de Alimentação e Veterinária (reference A002.2015).
Rat Study. All animal experiments were carried out in accordance with the
Danish Act on Experiments on Animals, and EU Directive 2010/63. A project
license was issued by the national authority. All animal experiments were
performed in accordancewith relevant regulations andguidelines and approved
by the Novo Nordisk Animal Welfare Body. Sprague–Dawley (SD) rats were
purchased from Charles River Laboratories and were housed under standard
conditions including a 12 h:12 h light:dark cycle, ∼21 °C, and water and food ad
libitum. In rat study 1, single-housed SD rats (Charles River Laboratories)
weighing ∼350 g were allowed to acclimatize in the BioDAQ (Research Diet,
Inc.) food hopper/Accusampler (Verutech AB) catheter system for 8 to 9 d prior
to surgery. Surgery was performed on day 1 and catheters (Tygon Microbore
Tubing) were placed in the left carotid artery and the right jugular vein in
isoflurane-anesthetized animals and filled with 100 IU/mL heparin in 0.9% NaCl
to prevent clotting. After 5 to 6 d of additional acclimatization the study was
initiated by a bolus infusion of vehicle or human recombinant GDF15 for 1 h
(83 mL/kg/min ± 0.24 mg/kg/h GDF15) followed by a maintenance intravenous
(iv) infusion throughout the rest of the study (73 mL/kg/min ± 0.04 mg/kg/h of
GDF15). Arterial blood samples were collected automatically using the Accu-
sampler system at prespecified time points (−65min, 0 min, 30 min, 1 h, 2 h, 4 h,
24 h, 48 h, 72 h, 96 h, and 120 h) where time point zero is at the end of bolus
infusion. A total of 200 μL of blood was collected and transferred to ice-cooled
ethylenediaminetetraacetic acid (EDTA) tubes and immediately centrifuged for
2 min at 4,500 × g at 4 °C and kept at −80 °C until analysis. Plasma levels of
GDF15 were measured using an in-house immunoassay. Plasma mouse corti-
costerone was measured using the mouse/rat corticosterone enzyme-linked
immunosorbent assay (EIA) (Cat# AC14F1, IDS) and rat ACTH was measured by
Milliplex kit (Cat# RPTMAG-86K, Merck-Millipore).
Human Endotoxemia. Human study 1 was performed in the Integrated Critical
Care Unit at South Tyneside and Sunderland Foundation Trust, supervised by
a critical care physician.
Ethical approval was granted by the Yorkshire and the Humber–South
Yorkshire Research Ethics Committee (17/YH/0021), and the study was spon-
sored by Newcastle upon Tyne Hospitals National Health System (NHS)
Fig. 6. GDF15 and FGF21 show a synergic action in mediating tunicamycin-
induced corticosterone rising. MS11: Corticosterone serum levels in wild-
type, Fgf21−/−, and Gdf15−/−:Fgf21−/− mice 6 h after tunicamycin adminis-
tration compared to vehicle control. Data are expressed as mean ± SEM, n =
3 to 7 per group. *P < 0.05 by ANOVA.
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Foundation Trust. Ten healthy male volunteers (mean age 25 y, range 18 to 25)
gave informed, written consent to receive intravenous administration of LPS
(Cat#94332B1, donated by the NIH) and injected intravenously as a bolus dose
of 2 ng/kg. Baseline measurements were undertaken between 8:00 and 10:30.
Human cortisol was measured using a chemiluminescent immunoassay (Cat#
313261, DiaSorin S.p.A.). Human GDF15 was measured using an electro-
chemiluminescent immunoassay on the MesoScale Discovery platform with
antibodies and standards from R&D Systems Europe. Cytokine concentrations
were measured using a human inflammatory cytokine cytometric bead array
(CBA) (Cat# 551811, BD Biosciences).
GDF15 Injection at Standard and Thermoneutral Housing Temperatures. For
mouse studies 1 and 2 (MS1 and MS2), human recombinant GDF15 (Cat# 4570,
BioVision Inc.) was prepared in saline and administered via subcutaneous (s.c.)
injection as a single dose in the morning (9 AM). For mouse studies, 12 to 14
human recombinant GDF15 (Cat# Qk017, Qkine) was administrated via s.c. in-
jection as a single dose in the morning (9 AM). At 1 h and/or 4 h posthuman
recombinant GDF15 treatment, mice were killed by CO2 inhalation and blood
was collected via cardiac puncture. Blood was collected in EDTA tubes (Becton
Dickinson and Company) and centrifuged to collect plasma, which was stored
at −80 °C until analysis. For MS1 and MS2, plasma human GDF15 was measured
using the human GDF15 Quantikine ELISA (R&D Systems) and plasma mouse
corticosterone was measured using the mouse corticosterone ELISA (Cat#
55-CORMS-E01, ALPCO) as per manufacturer instructions. For MS12 to MS14,
GDF15 was measured using the human GDF15 ELISA (Cat#DY957, R&D Systems,
BioTechne) and plasma mouse corticosterone was measured using the mouse
corticosterone EIA (Cat# AC14F1, IDS). Plasma leptin was measured using a Meso
Scale Discovery two-plex mouse metabolic immunoassay kit (Cat# K15124C,Meso
Scale Diagnostics).
Anti-GFRAL Studies. For mouse studies 3 and 15, the mice were injected intra-
peritoneally (i.p.) with anti-GFRAL monoclonal antibody (anti-GFRAL) (KyMab/
Sanofi) at a dose of 20 mg/kg and with vehicle control. These injections were
repeated twice at an interval of 1 d. The day after the last i.p. injection, either
human recombinant GDF15 (0.1 mg/kg, Qkine) or vehicle control were injected
s.c. Food intake and body weight were measured overnight and for 24 h. One
week later, the same anti-GFRAL-IgG experimental paradigm was repeated, but
this time, the day after the second injection the mice were injected with either
GDF15 or vehicle control at 9 AM and killed 1 h after. Blood was collected and
analyzed as described above.
Brain Processing and RNAScope Analysis. For mouse study 4, the mice were
injectedat 10:00AMeitherwithGDF15 (0.1mg/kgQkine) or vehicle control. One
hour postinjection mice were killed, and brain tissue was collected and fixed.
Simultaneous detection of mouse Fos and Crh was performed using Advanced
Cell Diagnostics (ACD) RNAScope 2.5 LS Duplex Reagent Kit (Cat# 322440, ACD),
RNAScope LS 2.5 Probe- Mm-Fos (Cat# 316928, ACD), and RNAScope 2.5 LS
Probe- Mm-Crh-C2 (Cat# 316098-C2, ACD). Positive (RNAScope 2.5 LS Duplex
Control Probes [PPIB-C1, Polr2A-C2]-Mm) and negative (RNAScope 2.5 LS Du-
plex Negative Control Probe [DapB-C1, DapB-C2]) controls were performed in
parallel (ACD). Slides were processed as previously described (65).
Drugs Studies. For mouse study 5, cohorts of adult Gdf15−/− mice and wild-
type littermate control mice were injected (i.p.) with either LPS (Cat# L2880,
Sigma) at 0.05 to 0.5 mg/kg or vehicle (phosphate-buffer saline [PBS]) and
killed by cervical dislocation. For mouse study 6, cohorts of adult Gdf15−/−
and wild-type (C57BL/6J) control mice were infected with E. coli and samples
were collected 4 h later. E. coli infections were performed as previously
described (66). After 4 h, mice were killed by cervical dislocation. For mouse
studies 7 and 8, cohorts of adult Gdf15−/− mice and wild-type littermate
control mice were used. A total of 10 mg/kg of cisplatin (Cat# NDC 0703-
5747-11, Teva) or saline was administered via i.p. injection as a single dose at
9 AM. After 6 h of treatment, mice were killed by CO2 inhalation. For mouse
studies 9 through 11, adult cohorts of Gdf15−/− mice, as well as wild-type
littermate control mice, were used. The animals were allocated to the ex-
perimental groups, matching body weight and age. Tunicamycin 0.1 mg/kg
(Cat# T7765-5MG, Sigma) or vehicle (5% dimethyl sulfoxide [Sigma] in PBS)
were injected i.p. at 8 to 9 AM. After 6 h of treatment, mice were killed.
Blood was analyzed as described above.
RNA Isolation/cDNA Synthesis for qPCR. For mouse studies 7 through 10, total
liver RNA (RNA)was extracted, purified, andanalyzed as previously described (20).
Quantification and Statistical Analysis. For the mouse studies, results were
statistically analyzed using Student’s t test or an analysis of variance (ANOVA)
test using Prism 9 (GraphPad Software, Inc). For the rat study, differences were
estimated from a repeatedmeasurements model with baseline assessment as a
covariate. For the human study, repeated measures with a post hoc Dunnett’s
test were used to compare each time point with baseline.
Data Availability. Further information and requests for resources and re-
agents should be directed to and will be fulfilled by the lead contact, Stephen
O’Rahilly (so104@medschl.cam.ac.uk). For requests regarding the anti-GFRAL
antibody used in this work please contact E-Chiang.Lee@kymab.com. This
study did not generate/analyze new datasets/codes. All study data are in-
cluded in the article and/or SI Appendix.
ACKNOWLEDGMENTS. This project is supported by the National Institute for
Health Research (NIHR) Cambridge Biomedical Research Centre and by the
Pfizer Worldwide Research, Development, and Medical Postdoctoral training
program. The views expressed are those of the authors and not necessarily
those of the NIHR or the Department of Health and Social Care. A.P.C., D.R.,
J.A.T., I.C., Y.C.L.T., and G.S.H.Y. are supported by the Medical Research Council
(MRCMetabolic Diseases Unit (MC_UU_00014/1). J.A.T. is supported by the NIHR
Clinical Lectureship (CL-2019-14-504). L.F.M. was supported by the European
Commission Horizon 2020 (ERC-2014-CoG 647888- iPROTECTION). M.R.C. is
supported by a Wellcome Trust Investigator Award (220268/Z/20/Z). Mouse
mantainence in Cambridge is supported by Gemini Chu and Hayley Forest, with
pathology support from J. Warner and the Histopathology Core (MRC Meta-
bolic Diseases Unit [MC_UU_00014/5] and Wellcome Trust Strategic Award
[100574/Z/12/Z]). S.O. is supported by the Wellcome Trust (WT 107064 and WT
095515/Z/11/Z), the MRC Metabolic Disease Unit (MC_UU_00014/1), and the
NIHR Cambridge Biomedical Research Centre and NIHR Rare Disease Transla-
tional Research Collaboration. We thank all the members of the Cambridge
Biochemical Assay Laboratory. We thank J. Jones and other members of the
Histopathology and In Situ Hybridization Core Facility, Cancer Research UK
Cambridge Institute, University of Cambridge, Li Ka Shing Centre. Fgf21−/−,
and Gdf15−/−:Fgf21−/− mice were a gift from D. B. Savage and A. Haider, Insti-
tute of Metabolic Science, University of Cambridge. We thank Aaron Fleming
for the mouse LPS study support. LPS for the human study was kindly provided
Dr. Anthony Suffredini (NIH). We would like to thank John Stansfield for sta-
tistical analysis for the studies performed at Pfizer. Professor Simpson is a NIHR
Senior Investigator. The views expressed in this article are those of the authors
and not necessarily those of the NIHR or the Department of Health and Social
Care. A.J.R. and A.J.S. are supported by the MRC SHIELD Antimicrobial
Resistance Consortium.
1. J. P. Herman et al., Regulation of the hypothalamic-pituitary-adrenocortical stress
response. Compr. Physiol. 6, 603–621 (2016).
2. A. V. Turnbull, C. L. Rivier, Regulation of the hypothalamic-pituitary-adrenal axis by
cytokines: Actions and mechanisms of action. Physiol. Rev. 79, 1–71 (1999).
3. R. S. Ahima et al., Role of leptin in the neuroendocrine response to fasting. Nature
382, 250–252 (1996).
4. Q. Liang et al., FGF21 maintains glucose homeostasis by mediating the cross talk
between liver and brain during prolonged fasting. Diabetes 63, 4064–4075 (2014).
5. J. V. Goldstone et al., The chemical defensome: Environmental sensing and response
genes in the Strongylocentrotus purpuratus genome. Dev. Biol. 300, 366–384 (2006).
6. T. L. Couch, A. W. Benton, The effect of the venom of the honey bee, Apis mellifera L.,
on the adrenocortical response of the adult male rat. Toxicon 10, 55–62 (1972).
7. A. Chisari, E. Spinedi, M. J. Voirol, A. Giovambattista, R. C. Gaillard, A phospholipase
A2-related snake venom (from Crotalus durissus terrificus) stimulates neuroendocrine
and immune functions: Determination of different sites of action. Endocrinology 139,
617–625 (1998).
8. K. Suzukit, K. Yamashita, K. Hirai, K. I. Kurouji, H. Yoshio, Adrenal 17-hydroxycorticosteroid
secretion in response to cyanide anoxia. Pflugers Arch. Gesamte Physiol. Menschen Tiere
285, 119–123 (1965).
9. H. Kenward, L. Pelligand, J. Elliott, Assessment of low-dose cisplatin as a model of
nausea and emesis in beagle dogs, potential for repeated administration. Exp. Brain
Res. 232, 2685–2697 (2014).
10. Y. Akiyama et al., Peripherally administered cisplatin activates a parvocellular neuronal
subtype expressing arginine vasopressin and enhanced green fluorescent protein in the
paraventricular nucleus of a transgenic rat. J. Physiol. Sci. 70, 35 (2020).
11. K. Shimada, T. J. Mitchison, Unsupervised identification of disease states from high-
dimensional physiological and histopathological profiles. Mol. Syst. Biol. 15, e8636
(2019).
Cimino et al. PNAS | 9 of 10









12. S. M. Lockhart, V. Saudek, S. O’Rahilly, GDF15: A hormone conveying somatic distress
to the brain. Endocr. Rev. 41, 610–642 (2020).
13. S. N. Breit, D. A. Brown, V. W. Tsai, The GDF15-GFRAL pathway in health and metabolic
disease: Friend or foe? Annu. Rev. Physiol. 83, 127–151 (2020).
14. S. E. Mullican et al., GFRAL is the receptor for GDF15 and the ligand promotes weight
loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157 (2017).
15. P. J. Emmerson et al., The metabolic effects of GDF15 are mediated by the orphan
receptor GFRAL. Nat. Med. 23, 1215–1219 (2017).
16. L. Yang et al., GFRAL is the receptor for GDF15 and is required for the anti-obesity
effects of the ligand. Nat. Med. 23, 1158–1166 (2017).
17. J. Y. Hsu et al., Erratum: Non-homeostatic body weight regulation through a
brainstem-restricted receptor for GDF15. Nature 551, 398 (2017).
18. H. Johnen et al., Tumor-induced anorexia and weight loss are mediated by the TGF-
beta superfamily cytokine MIC-1. Nat. Med. 13, 1333–1340 (2007).
19. L. Macia et al., Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food in-
take, body weight and improves glucose tolerance in mice on normal & obesogenic
diets. PLoS One 7, e34868 (2012).
20. S. Patel et al., GDF15 provides an endocrine signal of nutritional stress in mice and
humans. Cell Metab. 29, 707–718.e8 (2019).
21. D. M. Breen et al., GDF-15 neutralization alleviates platinum-based chemotherapy-
induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell
Metab. 32, 938–950.e6 (2020).
22. T. Borner et al., GDF15 induces anorexia through nausea and emesis. Cell Metab. 31,
351–362.e5 (2020).
23. Y. Xiong et al., Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from
mice to monkeys. Sci. Transl. Med. 9, eaan8732 (2017).
24. S. A. Hinke et al., Growth differentiation factor-15 (GDF-15) inhibits gastric emptying
in rodents as part of its anorectic mechanism of action. Diabetes 67 (2018).
25. T. Borner et al., GDF15 induces an aversive visceral malaise state that drives anorexia
and weight loss. Cell Rep. 31, 107543 (2020).
26. A. B. Klein et al., Pharmacological but not physiological GDF15 suppresses feeding
and the motivation to exercise. Nat. Commun. 12, 1041 (2021).
27. J. Wijnholds, K. Chowdhury, R. Wehr, P. Gruss, Segment-specific expression of the
neuronatin gene during early hindbrain development. Dev. Biol. 171, 73–84 (1995).
28. K. H. Kim et al., Growth differentiation factor 15 ameliorates nonalcoholic steato-
hepatitis and related metabolic disorders in mice. Sci. Rep. 8, 6789 (2018).
29. L. Buendgens et al., Growth differentiation factor-15 is a predictor of mortality in
critically ill patients with sepsis. Dis. Markers 2017, 5271203 (2017).
30. R. Altena et al., Growth differentiation factor 15 (GDF-15) plasma levels increase
during bleomycin- and cisplatin-based treatment of testicular cancer patients and
relate to endothelial damage. PLoS One 10, e0115372 (2015).
31. R. Stahrenberg et al., The novel biomarker growth differentiation factor 15 in heart
failure with normal ejection fraction. Eur. J. Heart Fail. 12, 1309–1316 (2010).
32. A. A. Worth et al., The cytokine GDF15 signals through a population of brainstem
cholecystokinin neurons to mediate anorectic signalling. eLife 9, e55164 (2020).
33. M. N. Silverman, B. D. Pearce, C. A. Biron, A. H. Miller, Immune modulation of the
hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol. 18,
41–78 (2005).
34. H. H. Luan et al., GDF15 is an inflammation-induced central mediator of tissue tol-
erance. Cell 178, 1231–1244.e11 (2019).
35. I. Santos et al., CXCL5-mediated recruitment of neutrophils into the peritoneal cavity
of Gdf15-deficient mice protects against abdominal sepsis. Proc. Natl. Acad. Sci. U.S.A.
117, 12281–12287 (2020).
36. T. Watanabe et al., Discrimination of genotoxic and non-genotoxic hepatocarci-
nogens by statistical analysis based on gene expression profiling in the mouse liver as
determined by quantitative real-time PCR. Mutat. Res. 747, 164–175 (2012).
37. T. E. Adolph et al., Weight loss induced by bariatric surgery restricts hepatic GDF15
expression. J. Obes. 2018, 7108075 (2018).
38. P. Navarra et al., Interleukins-1 and -6 stimulate the release of corticotropin-releasing
hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase
pathway. Endocrinology 128, 37–44 (1991).
39. M. J. van der Meer et al., Acute stimulation of the hypothalamic-pituitary-adrenal axis
by IL-1 beta, TNF alpha and IL-6: A dose response study. J. Endocrinol. Invest. 19,
175–182 (1996).
40. M. R. Bootcov et al., MIC-1, a novel macrophage inhibitory cytokine, is a divergent
member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. U.S.A. 94, 11514–11519
(1997).
41. J. Corre, B. Hébraud, P. Bourin, Concise review: Growth differentiation factor 15 in
pathology: A clinical role? Stem Cells Transl. Med. 2, 946–952 (2013).
42. K. Unsicker, B. Spittau, K. Krieglstein, The multiple facets of the TGF-β family cytokine
growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth
Factor Rev. 24, 373–384 (2013).
43. P. V. Sabatini et al., GFRAL-expressing neurons suppress food intake via aversive
pathways. Proc. Natl. Acad. Sci. U.S.A. 118, e2021357118 (2021).
44. T. L. Krukoff, K. H. Harris, J. H. Jhamandas, Efferent projections from the parabrachial
nucleus demonstrated with the anterograde tracer Phaseolus vulgaris leucoag-
glutinin. Brain Res. Bull. 30, 163–172 (1993).
45. H. Park, C. H. Kim, J. H. Jeong, M. Park, K. S. Kim, GDF15 contributes to radiation-
induced senescence through the ROS-mediated p16 pathway in human endothelial
cells. Oncotarget 7, 9634–9644 (2016).
46. H. Zheng et al., Hypoxia induces growth differentiation factor 15 to promote the
metastasis of colorectal cancer via PERK-eIF2α signaling. BioMed Res. Int. 2020,
5958272 (2020).
47. M. Kleinert et al., Exercise increases circulating GDF15 in humans. Mol. Metab. 9,
187–191 (2018).
48. G. R. Morrow, J. T. Hickok, P. L. Andrews, R. M. Stern, Reduction in serum cortisol after
platinum based chemotherapy for cancer: A role for the HPA axis in treatment-
related nausea? Psychophysiology 39, 491–495 (2002).
49. F. G. Schaap, A. E. Kremer, W. H. Lamers, P. L. Jansen, I. C. Gaemers, Fibroblast growth
factor 21 is induced by endoplasmic reticulum stress. Biochimie 95, 692–699 (2013).
50. S. O’Rahilly, GDF15-from biomarker to allostatic hormone. Cell Metab. 26, 807–808
(2017).
51. C. E. W. Steinberg, Arms Race Between Plants and Animals: Biotransformation System
in Stress Ecology: Environmental Stress as Ecological Driving Force and Key Player in
Evolution (Springer, 2012).
52. V. W. Tsai et al., Anorexia/cachexia of chronic diseases: A role for the TGF-β family
cytokine MIC-1/GDF15. J. Cachexia Sarcopenia Muscle 3, 239–243 (2012).
53. S. N. Breit, V. W. Tsai, D. A. Brown, Targeting obesity and cachexia: Identification of
the GFRAL receptor-MIC-1/GDF15 pathway. Trends Mol. Med. 23, 1065–1067 (2017).
54. T. Nakajima et al., Growth differentiation factor-15 (GDF-15) is a biomarker of muscle
wasting and renal dysfunction in preoperative cardiovascular surgery patients. J. Clin.
Med. 8, 1576 (2019).
55. M. S. Patel et al., Growth differentiation factor-15 is associated with muscle mass in
chronic obstructive pulmonary disease and promotes muscle wasting in vivo.
J. Cachexia Sarcopenia Muscle 7, 436–448 (2016).
56. W. J. Evans et al., Cachexia: A new definition. Clin. Nutr. 27, 793–799 (2008).
57. A. Melvin et al., GDF15 is elevated in conditions of glucocorticoid deficiency and is
modulated by glucocorticoid replacement. J. Clin. Endocrinol. Metab. 105, 1427–1434
(2020).
58. S. J. Baek, T. Eling, Growth differentiation factor 15 (GDF15): A survival protein with
therapeutic potential in metabolic diseases. Pharmacol. Ther. 198, 46–58 (2019).
59. T. A. Zimmers, J. C. Gutierrez, L. G. Koniaris, Loss of GDF-15 abolishes sulindac che-
moprevention in the ApcMin/+ mouse model of intestinal cancer. J. Cancer Res. Clin.
Oncol. 136, 571–576 (2010).
60. S. N. Breit et al., The TGF-β superfamily cytokine, MIC-1/GDF15: A pleotrophic cytokine
with roles in inflammation, cancer and metabolism. Growth Factors 29, 187–195
(2011).
61. T. Kempf et al., GDF-15 is an inhibitor of leukocyte integrin activation required for
survival after myocardial infarction in mice. Nat. Med. 17, 581–588 (2011).
62. G. A. Bonaterra et al., Growth differentiation factor-15 deficiency inhibits athero-
sclerosis progression by regulating interleukin-6-dependent inflammatory response
to vascular injury. J. Am. Heart Assoc. 1, e002550 (2012).
63. Q. Wu et al., Overproduction of growth differentiation factor 15 promotes human
rhinovirus infection and virus-induced inflammation in the lung. Am. J. Physiol. Lung
Cell. Mol. Physiol. 314, L514–L527 (2018).
64. R. Suriben et al., Antibody-mediated inhibition of GDF15-GFRAL activity reverses
cancer cachexia in mice. Nat. Med. 26, 1264–1270 (2020).
65. A. E. Adriaenssens et al., Glucose-dependent insulinotropic polypeptide receptor-
expressing cells in the hypothalamus regulate food intake. Cell Metab. 30, 987–996.e6
(2019).
66. H. G. Colaço et al., Tetracycline antibiotics induce host-dependent disease tolerance
to infection. Immunity 54, 53–67.e7 (2021).
10 of 10 | PNAS Cimino et al.
https://doi.org/10.1073/pnas.2106868118 Activation of the hypothalamic–pituitary–adrenal axis by exogenous and endogenous
GDF15
